
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suspension containing riboflavin, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved product lists riboflavin as its only active ingredient; in approved products it appears in kits, namely corneal cross-linking kits for eye use and multivitamin injection kits.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Riboflavin (vitamin B2) is a water-soluble B vitamin, taken by mouth or used in eye procedures, that a pharmacy may compound when prescribed.
Riboflavin, also called vitamin B2, is a water-soluble B vitamin. In the body it forms two coenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), which help release energy from food, support cell growth and red blood cell production, and help the body handle fats, drugs and steroids. It is found in eggs, organ meats, lean meats, milk and fortified grains, and deficiency is rare in the United States. Oral riboflavin is sold mainly as a dietary supplement. FDA-approved products containing it include the Photrexa and Epioxa ophthalmic kits (riboflavin 5'-phosphate), used with a UV light system for corneal collagen cross-linking in keratoconus, and injectable multivitamins. A prescriber might order riboflavin compounded in a form, strength or combination that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Riboflavin taken by mouth has no FDA drug label, so there are no labeled warnings or interaction lists for it as a single oral product. NIH's Office of Dietary Supplements (ODS) reports no observed toxicity from high food intakes, and no tolerable upper intake level has been set, though experts still advise caution with very large amounts. In migraine studies, ODS notes that side effects such as discolored urine were minimal. ODS says riboflavin is not known to have clinically relevant interactions with medicines. Light breaks riboflavin down, which is why long phototherapy for newborn jaundice can lower levels. For the cross-linking eye products, both labels say the procedure should not be done during pregnancy; the Photrexa label warns of corneal ulceration (ulcerative keratitis), and the Epioxa label advises caution with a history of herpes eye infection. MedlinePlus lists higher daily needs in pregnancy and breastfeeding; no LactMed record was found. Tell your prescriber or pharmacist about all medicines and supplements you take, and talk to them about side effects.
Riboflavin is the precursor of FMN and FAD, which catalyze oxidation and reduction reactions in many metabolic pathways; FAD is needed to convert tryptophan to niacin, and FMN to activate vitamin B6 (ODS). Under corneal cross-linking conditions, riboflavin 5'-phosphate acts as a photoenhancer that generates singlet oxygen (Photrexa label). ODS reports that most oral riboflavin is absorbed in the proximal small intestine, absorption from large single doses is limited, little is stored (liver, heart, kidneys), and excess is excreted in urine. Labeled indications: corneal collagen cross-linking with the KXL System for progressive keratoconus and corneal ectasia after refractive surgery (Photrexa and Photrexa Viscous, NDA); epithelium-on cross-linking for keratoconus from age 13 (Epioxa and Epioxa HD, NDA). Epioxa is contraindicated in aphakic or pseudophakic eyes without a UV-blocking lens and with benzalkonium chloride hypersensitivity; Photrexa lists no contraindications. Oral riboflavin has no FDA-approved indication. ODS summarizes trials for migraine prevention (fewer attacks in one adult trial, mixed pediatric results) and describes supplementation in riboflavin transporter deficiency; these are not FDA-approved indications. Deficiency signs include angular cheilitis, sore throat, mucosal swelling, skin changes and anemia. Not a controlled substance. Dosing is per prescriber.
Shake the bottle well before every dose so the medication is evenly mixed. Measure with the oral syringe or dosing cup provided, using the milliliter markings, and never a kitchen spoon. Take it by mouth as your label directs. Rinse the syringe after use and recap the bottle.
Water-based suspensions are aqueous preparations. Under USP <795>, a preserved suspension usually carries a beyond-use date of up to 35 days at room temperature or refrigerated; an unpreserved one is refrigerated for up to 14 days. Oil-based suspensions are nonaqueous and may carry up to 90 days. Your label states storage and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally